
It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.
It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.
Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. companies are turning to Russa after having secured approval for 108 trials there in 2018.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: